TriviumVet advance their first feline product, a potential treatment for HCM in cats

TriviumVet commence clinical study of first-in-disease treatment for HCM in cats We are delighted to announce the initiation of a ground-breaking clinical study in client-owned cats to evaluate the effectiveness of our patented delayed-release rapamycin formulation (TRIV-203F) in treating hypertrophic cardiomyopathy (HCM). Rapamycin background Results of previous laboratory animal studies and effects observed in human […]